RE: Agenix WKN : 936435
Die australische Biotechschmiede hat exellente Halbjahres-Zahlen vorgelegt.
Das Halbjahresergebnis war Exellent.
Der Nachsteuergewinn stieg um 435 % im ersten Halbejahr !
RECORD CONTRIBUTION FROM DIAGNOSTIC SUBSIDIARY AGEN
Biotechnology company Agenix Limited (ASX: AGX] today announced a
435% increase in after-tax profit to $1.7 million for the six months
to December 31, 2001.
This compares to a profit of $0.3 million for the corresponding
six-month period to December 2000.
Umsatzanstieg um 66 % Gewinn anstieg um 435 %
Key group financials for the period were:
2001 (6 MTHS) 2000(6 MTHS) % INCREASE
Group Sales $18.8 million $11.3 million 66%
Agen $9.5 million $6.1 Million 55%
Milton $9.0 million $5.0 million 80%
Jemaka $0.3 million $0.2 million 52%
Operating Profit $1.9 million $0.5 million 272%
Tax $0.2 million $0.2 million -
Net Profit $1.7 million $0.3 million 435%
EBITDAR $3.7 million $2.3 million 59%
EPS 1.1 cents $0.3 cents 270%
Ein wirklich geiles Ergebnis.
Das Umsatzwachstum is unfassbar.
SOM